Ameriprise
TARO

Ameriprise’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Ameriprise’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-227,635
Closed -$9.64M – 3965
2024
Q1 		$9.64M Sell
227,635
-79,590
-26% -$3.35M ﹤0.01% 1820
2023
Q4 		$12.8M Buy
307,225
+2,916
+1% +$108K ﹤0.01% 1582
2023
Q3 		$11.5M Buy
304,309
+74,054
+32% +$2.78M ﹤0.01% 1585
2023
Q2 		$8.73M Buy
230,255
+23,292
+11% +$731K ﹤0.01% 1888
2023
Q1 		$5.03M Sell
206,963
-72,070
-26% -$2.1M ﹤0.01% 2318
2022
Q4 		$8.1M Buy
279,033
+95,893
+52% +$2.84M ﹤0.01% 1920
2022
Q3 		$5.49M Buy
183,140
+25,865
+16% +$892K ﹤0.01% 2148
2022
Q2 		$5.69M Sell
157,275
-65,568
-29% -$2.5M ﹤0.01% 2185
2022
Q1 		$9.64M Buy
222,843
+71,489
+47% +$3.34M ﹤0.01% 1947
2021
Q4 		$7.58M Sell
151,354
-36,060
-19% -$2.02M ﹤0.01% 2185
2021
Q3 		$11.9M Buy
187,414
+3,568
+2% +$247K ﹤0.01% 1710
2021
Q2 		$13.2M Buy
183,846
+99,945
+119% +$7.34M ﹤0.01% 1689
2021
Q1 		$6.19M Buy
83,901
+1,736
+2% +$132K ﹤0.01% 2262
2020
Q4 		$6.03M Buy
82,165
+68,710
+511% +$4.42M ﹤0.01% 2139
2020
Q3 		$738K Buy
13,455
+1,380
+11% +$85.9K ﹤0.01% 3097
2020
Q2 		$803K Sell
12,075
-4,882
-29% -$327K ﹤0.01% 3012
2020
Q1 		$1.04M Buy
16,957
+1,500
+10% +$111K ﹤0.01% 2804
2019
Q4 		$1.36M Buy
15,457
+300
+2% +$25.3K ﹤0.01% 2928
2019
Q3 		$1.14M Hold
15,157
– – ﹤0.01% 2968
2019
Q2 		$1.29M Buy
15,157
+1,950
+15% +$193K ﹤0.01% 2962
2019
Q1 		$1.43M Buy
+13,207
New +$1.31M ﹤0.01% 2895
2014
Q4 		– Sell
-221
Closed -$34K – 4501
2014
Q3 		$34K Buy
+221
New +$33.3K ﹤0.01% 4190

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Ameriprise's TARO Position: Q2 2024 in Review

Ameriprise sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 227,635 shares — an estimated $9.64M sold.

Ameriprise first reported a position in TARO in Q3 2014 and held it in 22 quarters. The position peaked at $13.2M in Q2 2021. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • Ameriprise reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • Ameriprise sold 227,635 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $9.64M.
  • Ameriprise first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2014 and held it in 22 quarters.
  • Ameriprise's Taro Pharmaceutical Industries Ltd. position peaked at $13.2M in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on Ameriprise's 13F filing for Q2 2024, filed 14 Aug 2024.